Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2021 / Article
Special Issue

Molecular Approaches Evaluating the Antioxidant Activity of Flavonoids in Health and Disease

View this Special Issue

Review Article | Open Access

Volume 2021 |Article ID 9952578 | https://doi.org/10.1155/2021/9952578

Guowei Gong, Yuzhong Zheng, Yang Yang, Yixuan Sui, Zhen Wen, "Pharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus", Evidence-Based Complementary and Alternative Medicine, vol. 2021, Article ID 9952578, 9 pages, 2021. https://doi.org/10.1155/2021/9952578

Pharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus

Academic Editor: Oana Cioanca
Received19 Mar 2021
Revised21 Apr 2021
Accepted29 Apr 2021
Published07 May 2021

Abstract

Astragalus is a popular Materia Medica in China, and it could be applied in the treatment of various diseases. It contains a variety of chemically active ingredients, such as saponins, flavonoids, and polysaccharides. Plant-derived bioactive chemicals are considered natural, safe, and beneficial. Among the infinite plant-identified and isolated molecules, flavonoids have been reported to have positive effects on human health. Calycosin is the most important active flavonoid substance identified predominantly within this medicinal plant. In recent years, calycosin has been reported to have anticancer, antioxidative, immune-modulatory, and estrogenic-like properties. This review collected recent relevant literatures on calycosin and summarized its potential pharmaceutical properties and working mechanism involved, which provided solid basis for future clinical research.

1. Introduction

The development of traditional Chinese medicine (TCM) has a history of thousands of years, and it has accumulated myriad medical experience and summarized pharmacological effects of Materia Medica playing a pivotal role in modernization of TCM [1, 2]. With the development of modern medicine, the pharmaceutical properties of raw herbal extract can no longer satisfy today’s sophisticated biomedical research. The bioactive molecules selected and isolated from plant are more suitable as potential medicine [3, 4]. In fact, plant-derived chemicals are associated with drug development, such as Taxol isolated from Taxus chinensis and camptothecin identified and enriched from Camptotheca acuminata.

Astragalus membranaceus, Huangqi in Chinese, as a classic traditional herbal medicine, is commonly used in a variety of traditional Chinese medicine prescriptions [5, 6]. The major pharmaceutical functions of this Materia Medica are boosting immune and hematopoietic systems [7, 8]. Previous studies have reported that a plethora of flavonoids have been identified and isolated from Astragalus. Flavonoids are classified as polyphenolic compounds and they are ubiquitously enriched in the plant kingdom [9, 10]. It is estimated that over 4000 flavonoids have been reported and identified, and they could be clustered into 8 subclasses, that is, flavanole, flavanonole, chalkone, anthocyanidine, aurone, flavone, flavanone, and isoflavone [9, 10]. Calycosin is the most enriched isoflavone found abundantly in Astragalus. This molecule has gained attention for its myriad medical functions both in vitro and in vivo [2, 5, 6, 11]. Hence, this review emphasizes the effects of calycosin on anticancer, antioxidative, immune-modulatory, and estrogenic-like properties.

2. Pharmacological Activities of Calycosin

2.1. Anticancer Functions

Breast cancer is one of the most common cancers threatening women globally and it accounts for approximately 15% of female cancer-related deaths in the United States [12, 13]. Human breast cancer is classified into estrogen receptor-positive (ER+) and estrogen receptor-negative (ER−) subtypes. Tian et al. have reported that calycosin was able to inhibit both ER− and ER+ breast cancer cell proliferation in a dose-dependent manner and the inhibitory effects were associated with noncoding RNA WDR7-7 expression level by inducing G-protein coupled estrogen receptor 30 (GPR30) and RASD1 via Erk1/2 and Akt transduction pathway [14, 15]. The apoptosis-related protein, cleaved caspase 3/9, and Bax were significantly stimulated under the treatment of calycosin in ER + cancer cell type MCF-7 [14]. Li group published similar data and confirmed that calycosin at 150 μM was capable of blocking MCF-7 and T47D cells migration and invasion by wound healing and Transwell assays [16]. Interestingly, calycosin at 2 μmol/L already triggered MCF-7 cell apoptosis by flow cytometry analysis [17]. Additionally, treatment of calycosin could downregulate forkhead box P3, vascular endothelial growth factor (VEGF), and matrix metalloproteinase 9 (MMP9) in MCF-7 and T47D [17]. Furthermore, Chen group (2014) confirmed that calycosin induced ER+ MCF-7 cell apoptosis via the blocking insulin-like growth factor 1 receptor (IGF-1R) pathway after 48-hour treatment [18]. On the other hand, Wu et al. (2019) found that the application of calycosin decreased invasive and migratory effects in ER-breast cancer MDA-MB231 cells by suppressing Rab27B, ß-catenin, and VEGF levels. More importantly, the inhibitory activities under the challenge of calycosin were recovered by the overexpression of Rab27B [19].

Colorectal cancer has a high mortality rate, which is also named as bowel cancer, colon cancer, or rectal cancer, claiming at least 500 thousand lives every year globally [20, 21]. Colorectal cancer is the third highest incidence of all cancers worldwide. The early symptoms of colorectal cancer are hard to detect, and the terminal stage of colorectal cancer is barely treated due to lack of effective biomarkers for clinical screening [22]. The study found that the potential targets of calycosin on colorectal cancer were ERα, ERβ, ATP-binding cassette subfamily G member 2, breast cancer type 1 susceptibility protein, CYP19A1, and epidermal growth factor receptor (EGFR) [22]. Therefore, these targets could be used as monitor for colorectal cancer treatment. Besides, the in vitro and in vivo against colorectal properties of calycosin have been widely documented [2325]. Zhao et al. have published that calycosin suppressed colorectal cancer cell line SW480 dose-dependently by Hoechst 33258 assay [25]. Furthermore, the xenograft tumor size in nude mice was decreased by the calycosin treatment [25]. Impressively, calycosin significantly enhanced autophagy specific protein expressions, that is, Beclin-1 and LC-3II, after 48-hour incubation in cultured HT-29 cells [26]. However, cotreatment of HT-29 with IGF-1 could recover calycosin-induced cell autophagy. Wang found that calycosin inhibited colorectal cancer proliferation and migration by enhancing BATF2 to target plasminogen activator inhibitor-1 [27]. Moreover, this molecule was able to abolish transforming growth factor ß- (TGF-β-) induced epithelial-to-mesenchymal transition via altering Wnt mechanism [27]. In addition, calycosin robustly restricted HCT-116 cells viability and invasiveness by enhancing ERβ and phosphatase and tensin homolog (PTEN) expressions [28].

Osteosarcoma is the most common malignant bone tumor with potential for invasion and metastasis; however, the current chemotherapy for osteosarcoma is not yet perfect [29, 30]. Calycosin is evidenced to induce MG-63 apoptosis, reduce cell proliferation, and decrease matrix metalloproteinase 2 (MMP2) and proliferating cell nuclear antigen expression after 48-hour incubation [31]. In tumor-bearing nude mice study, the tumor size and weight were reduced in calycosin-treated group [31]. Protein expression levels of IκBα and interleukin-6 (IL-6) were attenuated after calycosin interference for 3 weeks [31]. The data was in line with Wang et al.’s work published in 2018; they found that calycosin suppressed PI3K/AKT/mTOR pathway. In the MG-63 xenografts nude mice, calycosin inhibited tumor growth and also regulated phosphorylations of PI3K/Akt [3133]. Hence, Table 1 summarizes the anticancer functions of calycosin.


BiomarkersModelReference

Cleaved caspase 3/9 upregulation; enhanced Bax/Bcl-2 ratioMCF-7 cells; MDA-MB231 cellsTian et al. [14]; Tian et al. [15]
Reduced cell migration and invasion; enhanced apoptosis rate via blocking IGF-1R pathway; downregulated VEGF and MMPMCF-7 cells; T47D cellsLi et al. [16]; Chen et al. [17]; Chen et al. [18]
Downregulation of Rab27B and β-cateninMDA-MB-231 cellsWu et al. [19]
Abnormal expression levels of ERα, ERβ, ATP-binding cassette subfamily G member 2, breast cancer type 1 susceptibility protein, p450, and EGFROMIM dataHuang et al. [22]
Colorectal cancer proliferationSW480 cellsZhao et al. [25]
Beclin-1 and LC-3II overexpressionHT-29 cellsEI-kott et al. [26]
Upregulation of ERβ and PTENHCT-116 cellsChen et al. [28]
Induced osteosarcoma apoptosis and decrease MMP2MG-63 cellsQiu et al. [31]
Reduced tumor size and PI3K/Akt phosphorylationNude miceWang et al. [32]; Qiu et al. [31]; Tian et al. [33]

2.2. Antioxidative Properties

Oxidative stress is a phenomenon triggered by the excessive production and accumulation of reactive oxygen species (ROS) in cells and finally leads to dysfunction of tissues [34, 35]. Calycosin has been evidenced to protect doxorubicin-induced oxidative stress in cultured cardiomyocyte by inhibiting ROS generation via enhancing antioxidant enzymatic activities, that is, glutathione peroxidase, catalase, and superoxide dismutase (SOD) (Table 2) [36]. Moreover, the levels of sirtuin 1-NOD-like receptor protein 3 and related proteins were elevated after calycosin was incubated for 24 hours both in vitro and in vivo [36]. Liu found that calycosin could also attenuate H2O2-induced H9C2 cell apoptosis rate in a dose-dependent manner [38]. Pretreatment with ER antagonist, ICI 182,780, negated the protective effect of calycosin against H2O2-induced apoptosis [37, 38]. Elsherbiny et al. (2020) have reported that calycosin showed potential effects on type 2 diabetes mellitus treatment after 4-week administration [40]. The contents of IL33/ST2 mRNA were enhanced and levels of p65, tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β) and TGF-β were downregulated in calycosin treatment mice (Table 2) [39, 40]. Interestingly, calycosin reduced oxidative stress in intracerebral hemorrhage mouse model by stimulating Nrf-2 protein expression [42]. Oral administration of calycosin at 25 or 50 mg/kg/day was able to enhance amylase and lipase levels in serum in acute pancreatitis rat model [41]. The cytokine levels after calycosin treatment were mitigated [41]. Additionally, calycosin was able to decrease cerulein-induced pancreatic edema, inhibiting myeloperoxidase activity and stimulating SOD activity [41]. Studies have shown that calycosin can extend the lifespan of C. elegans, and this extension is related to the antioxidant capacity by enhancing stress resistance capacity and reducing the accumulation of ROS [43]. Lu group (2017) published that calycosin required insulin signaling involvement to promote lifespan extension [43]. On the other hand, they observed that calycosin can enhance the nuclear translocation of the core transcription factor DAF-16/FOXO, rather than the conservative stress response transcription factor SKN-1/Nrf-2 [43].


BiomarkersModelReference

Enhance glutathione peroxidase, catalase, and superoxide dismutase enzymatic activitiesH9C2 cells and male Kunming miceZhai et al. [36]
Reduced H2O2-induced cell apoptosis rateH9C2Chen et al. [37]; Liu et al. [38]
Downregulation of cytokine levels and IL33/ST2 mRNA levelType 2 diabetes mellitus rat modelWang & Zhao [39]; EIsherbiny et al. [40]
Stimulating Nrf2 expression and SOD levelsIntracerebral hemorrhage mouseMa et al. [41]; Chen et al. [42]
Prolong lifespan and stimulate SOD levelsC. elegansLu et al. [43]

2.3. Anti-Inflammatory Functions

The anti-inflammatory properties of calycosin were widely documented on lipopolysaccharide- (LPS-) induced RAW 264.7 cells [41, 44]. Calycosin significantly attenuated nitric oxide (NO), prostaglandin E2 (PGE2), TNF-α, IL-1β, and IL-6 releases, and the anti-inflammatory properties had been confirmed by NF-κB and MAPK signal pathways [44]. The effective dosage was from 30 nM to 5 μM, and the inhibitory function was dose-dependent. Besides, calycosin could also diminish inflammatory cell markers CD68 and F4/80 mRNA levels in a dose-dependent manner [45].

Calycosin was reported to possess renal protective functions in high-fat diet-induced type 2 diabetes mellitus rat model by altering SOD and TGF-β content in renal tissues as compared to the sham group [40]. Zhang et al. published similar data and reported that this molecule was able to effectively alleviate kidney injury in diabetic kidneys of db/db mice after treatment for 28 days (Table 3) [50]. The serum contents of inflammatory cytokines were reduced via suppressing IκBα and NF-κB p65 [50]. Additionally, fed glucose level in db/db obese mice was declined after calycosin administration which was proposed to be related to the anti-inflammatory effects [45]. Reduced serum triglyceride levels, alleviated insulin resistance, and glucose intolerance were observed in calycosin-treated mice compared with the vehicle-treated controls [45].


BiomarkersModelReference

Declined NO, PGE2, TNF-α, and other cytokine release activitiesRAW 264.7 cellsDong et al. [44]; Ma et al. [41]
Reduced CD68 and F4/80 mRNA levelsRaw 264.7Hoo et al. [45]
Enhanced SOD and TGF-β contentsType 2 diabetes mellitus rat modelEIsherbiny et al. [40]
Reduced IκBα and NF-κB p65 protein translational levels and alleviated insulin resistancedb/db obese miceHoo et al. [45]
Alleviated inflammatory responses and cytokine levels via attenuating Erk1/2 and NF-κB pathwaysHepatocyte cell line; HUVECFigarola et al. [46]; Kim et al. [47]; Cheng et al. [48]; Xu et al. [49]

Xu et al. found that calycosin was able to relieve advanced glycation end products- (AGE-) induced inflammation both in vitro and in vivo [49]. AGEs act as the central role in vasculitis development by recruiting the receptor for AGE overexpression (Table 3) [49]. Calycosin was able to diminish vasculitis development by downregulating the AGEs-induced overexpression of receptor for advanced glycation end products (RAGE) and proinflammatory cytokines in both rat and HUVECs [46]. ERK1/2 and NF-κB pathways were involved and evidenced by Kim et al. and Cheng et al. after calycosin presence for 4 hours [47, 48].

2.4. Estrogenic-Like Properties
2.4.1. Osteogenic Functions of Calycosin

Women suffering from menopause have higher risk of getting osteoporosis. The role of calycosin in preventing osteoporosis is widely reported [51, 52]. The proliferation and differentiation capacities of MG-63 were determined with and without calycosin presence [52]. From the results, calycosin was able to stimulate osteoblast differentiation dose-dependently [52]. The data was further confirmed in the rat primary cultured osteoblast. Data implied that the alkaline phosphatase (ALP) level and Runx2 were significantly enhanced after exposure of calycosin for 48 hours [52, 53]. Fang group found that calycosin could also modulate GSK-3β pathway for stimulating osteoblast differentiation which was further confirmed by its specific inhibitor GSK1904529A after revealing ALP, Col1a1, and Runx2 expression levels [54]. Bone mineral density was robustly enhanced in ovariectomized (OVX) rats after administration of calycosin for 12 weeks [51]. Elevated serum level of ALP and declined tartrate-resistant acid phosphatase (TRAP) level were observed [51]. Calycosin could also stimulate osteoprotegerin transcriptional and translational activities and downregulate RANKL expression level in calycosin group as compared with OVX group, and these alternations were proposed to be correlated with MAPK pathway. On the other hand, calycosin was able to abolish RANKL-induced osteoclast formation from primary bone marrow macrophages dose-dependently after 24-hour incubation [55]. Therefore, calycosin may be useful as a therapeutic agent for bone loss-associated diseases.

2.4.2. Hematopoietic Functions of Calycosin

One symptom of estrogen deficiency is anemia [7]. Several lines of evidence suggested that calycosin could stimulate the expression of erythropoietin (EPO), the central regulator of red blood cell mass, in cultured human embryonic kidney fibroblasts (HEK293T) after exposure of calycosin for 24 hours [7, 8, 11, 35]. The calycosin-induced EPO expression was mediated by HIF-1α from western blotting results [56]. The in vivo experiments showed that calycosin could enhance the number of RBCs, WBCs, PLTs, and content of Hb in peripheral blood and the area of bone marrow hematopoietic tissue [57]. The serum contents of thrombopoietin, EPO, granulocyte-macrophage colony stimulating factor, colony of CFU-GM, CFU-MK, CFU-E, and BFU-E were also enriched after calycosin treatment [57]. The animal experiments showed that this agent reduced G0/G1 cells and increased G2/M cells in hematopoietic stem cells.

2.5. Neuroprotective Functions

The neuroprotective functions of calycosin were determined both in vitro and in vivo. Administered with different concentration of calycosin from 7.5 mg/kg/day to 30 mg/kg/day, reduced malondialdehyde (MDA) and ROS contents were observed in calycosin-treated ischemia reperfusion rats [58]. However, the SOD activity was induced in the calycosin-treated ischemia reperfusion rats [58]. Calycosin could also stimulate ERβ, miR-374, and Bcl-2 protein expression levels in middle cerebral artery occlusion rats from western blotting data [59]. Similar protective effects of calycosin were evidenced in vitro by utilizing PC12 neuronal cell line with pretreatment of l-glutamate or xanthine (XA)/xanthine oxidase (XO) [60, 61]. Calycosin showed potential neuroprotective functions by blocking XA/XO-induced cell apoptosis at ∼50% and the EC50 of 0.05 mg/L and an IC50 of approximately 50 mg/L [6062]. Interestingly, calycosin shows promising therapeutic value on Alzheimer’s disease in APP/PS1 transgenic mice [63]. Intraperitoneally injected calycosin, the diminished hippocampal beta amyloid, Tau protein, IL-1β, TNF-α, acetylcholinesterase, and MDA levels were observed and the inhibitory effects were in a dose-dependent manner [63]. The maximal blockage concentration was revealed at 40 mg/kg/day. Yang found that calycosin could also mitigate Parkinson’s disease in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- (MPTP-) induced Parkinson’s disease mice [64]. From the results, Yang et al. confirmed that calycosin treatment mitigated the behavioral dysfunctions and inflammatory responses in MPTP-induced PD mice via NF-κB/MAPK pathways [64].

3. Pharmacokinetics of Calycosin

Because of hydroxyl groups found within the chemical structure of calycosin, they are metabolized to glucuronide by phase II metabolic enzymes such as UDP-glucuronosyltransferases from the intestine and liver after oral administration [65]. In addition to the role of metabolism, absorption, hydrolysis, efflux, and intestinal circulation in the intestinal tract also participate in the disposal of calycosin in the body, affecting their systemic and local bioavailability [66].

Studies have shown that, after oral administration of Astragalus water extract, the enriched content of calycosin-7-O-β-glucoside is detected in plasma, indicating that calycosin-7-O-β-glucoside can enter the intestinal cells in a prototype form and be metabolized [66, 67]. In the study, it was found that, after administration of calycosin by oral gavage, calycosin-7-O-β-glucoside can be detected in the plasma, which shows that calycosin-7-O-β-glucoside can penetrate the cell membrane in a prototype form and undergo further metabolism [68]. This indicates that calycosin-7-O-β-glucoside may directly pass through the cell membrane in a prototype form without hydrolysis [69]. Using Caco-2 cells to study the absorption and transport characteristics of calycosin and its glucoside, it was found that calycosin and calycosin-7-O-β-glucoside are mainly absorbed in the form of passive diffusion, and the absorption process will not be affected by inhibitors of MATEs such as P-gp and MRP2 [69, 70]. Calycosin can be metabolized in human liver microsomes to generate two glucuronides. UGT1A1 and UGT1A9 are the major metabolic enzyme subtypes that generate these two glucuronides, respectively [71]. On the other hand, after oral administration of calycosin, the calculated bioavailability of calycosin-7-O-β-glucoside was only 0.304%, indicating that hydrolyzing is an important process of metabolism in vivo [72, 73]. However, glucoside hydrolase is solely present in the intestine and liver of rats. In order to confirm the hydrolysis site of calycosin-7-O-β-glucoside, the pharmacokinetics of calycosin-7-O-β-glucoside injection in rats were investigated because the drug was directly absorbed by the hepatic portal vein after intraperitoneal injection [74]. The drug will not be processed through the intestine, so as to exclude the effect of the intestine on the calycosin-7-O-β-glucoside treatment in the body [75]. The results show that the drug time curve of calycosin-7-O-β-glucoside and its metabolites is completely different from that of calycosin-7-O-β-glucoside after oral administration.

4. Chemical Interactions

As the main bioactive molecule isolated from Astragali Radix, the pharmacological activity of calycosin is not performed alone but by the joint action of multiple chemical substances. Cotreatment of calycosin with other biochemicals identified from Astragali Radix, that is, formononetin, ononin and astragaloside, showed effective therapeutic functions as compared to single compound. The study found that the expression levels of drug-metabolizing enzymes, such as CYP3A4, CYP2B6, CYP2E1, UGT1A, and efflux transporters, that is, P-gp, MRP2, BCRP, and MRP3, were increased in a dose-dependent manner in the drug combination group [76]. Zheng et al. found that cotreatment of calycosin with formononetin stimulated EPO expression in a dose- and concentration-dependent manner in cultured HEK 293 cells. The hematopoietic functions of these combinations were even stronger than the positive control [77, 78]. Furthermore, Zhang et al. reported that flavonoid combination containing formononetin and calycosin at weight ratio of 1 : 5 showed the best hematological functions on anemic rat after drug treatment [79].

The research of calycosin in modern medicine is no longer confined to a single compound or Astragali Radix. More and more scientists have discovered the combination of multiple substances enjoying a broad spectrum in disease treatment by “Fu Fang.” Astragali Radix and Angelicae Sinensis Radix are usually combined together clinically [35, 52]. Cotreatment of calycosin and Astragali Sinensis Radix-derived ferulic acid protected bleomycin-induced pulmonary fibrosis in rats, and this action was believed via blocking NOX4 expression [80]. Furthermore, combination of calycosin and ferulic acid showed better immune-modulatory pharmaceutical activities in Raw 264.7 and inducing blood vessels in HUVECs and Zebra fish [8185]. Administration of calycosin and ferulic acid attenuates cytokine and inflammatory mediators’ releases in atopic dermatitis-like mouse [85].

5. Conclusion

Calycosin serves as a common dietary flavonoid and is consumed in daily cuisine and/or TCM decoction. Additionally, there are myriad of formulae containing calycosin at different dosage forms either alone or in combination with other bioactive molecules in market. The pharmaceutical functions of calycosin on anticancer, antioxidative, immune-modulatory, and estrogenic-like properties were summarized. We believe the potential pharmaceutical value of calycosin is still behind the veil, and which motivating us to discover more in the future. The in vitro and in vivo pharmaceutical functions do not directly translate into the clinic because of bioavailability and biotransformation influenced by gut microbiota. Considering various compositions of microbiota between individuals, the fluctuating process of bioavailability and biotransformation mediated by gut microbiota could have a consequential effect of calycosin and its metabolites in plasma, finally leading to diverse clinic functions. Hence, gut microbiota-induced bioavailability and biotransformation of calycosin and its metabolites should be taken into consideration before clinical application.

Abbreviations

ALP:Alkaline phosphatase
EGFR:Epidermal growth factor receptor
EPO:Erythropoietin
ER−:Estrogen receptor-negative
ER+:Estrogen receptor-positive
GPR30:G-protein coupled estrogen receptor 30
IGF-1R:Insulin-like growth factor 1 receptor
IL-1β:Interleukin-1β
IL-6:Interleukin-6
LPS:Lipopolysaccharide
MMP2:Matrix metalloproteinase 2
MMP9:Matrix metalloproteinase 9
NO:Nitric oxide
OVX:Ovariectomized
PGE2:Prostaglandin E2
PTEN:Phosphatase and tensin homolog
RAGE:Receptor for advanced glycation end products
ROS:Reactive oxygen species
SOD:Superoxide dismutase
TCM:Traditional Chinese medicine
TGF-β:Transforming growth factor ß
TNF-α:Tumor necrosis factor α
TRAP:Tartrate-resistant acid phosphatase
VEGF:Vascular endothelial growth factor
MDA:Malondialdehyde
XA/XO:Xanthine/xanthine oxidase
MPTP:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Data Availability

The data used in this paper are available upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Guowei Gong and Yang Yang wrote the main text. Yuzhong Zheng and Zhen Wen were responsible for polishing the manuscript. Yang Yang and Yixuan Sui formatted the references. All authors read and approved the final version of manuscript.

Acknowledgments

This work was supported by the Guizhou Provincial Natural Science Foundation (QKH-J [2020] 1Y377), Zunyi Science and Technology Project (ZSKHHZZ(2020)85), Science and Technology Program of Guizhou Province (QKPTRC[2019]-024), Zunyi Medical University for the Doctoral Program (F-937), Guangdong Key Laboratory for Functional Substances in Medicinal Edible Resources and Healthcare Products (2021B1212040015), Science and Technology Program of Guangdong Province (2018A030307074), and National Natural Science Foundation of China (22078198).

References

  1. H. Q. Lin, A. G. W. Gong, H. Y. Wang et al., “Danggui buxue tang (astragali Radix and Angelicae sinensis Radix) for menopausal symptoms: a review,” Journal of Ethnopharmacology, vol. 199, pp. 205–210, 2017. View at: Publisher Site | Google Scholar
  2. A. G. Gong, R. Duan, H. Y. Wang et al., “Evaluation of the pharmaceutical properties and value of Astragali Radix,” Medicines, vol. 5, no. 2, 2018. View at: Publisher Site | Google Scholar
  3. C. A. Espinosa-Leal, C. A. Puente-Garza, and S. García-Lara, “In vitro plant tissue culture: means for production of biological active compounds,” Planta, vol. 248, no. 1, pp. 1–18, 2018. View at: Publisher Site | Google Scholar
  4. E. Lautié, O. Russo, P. Ducrot et al., “Unraveling plant natural chemical diversity for drug discovery purposes,” Front Pharmacol, vol. 11, 2020. View at: Publisher Site | Google Scholar
  5. A. G.-W. Gong, N. Li, K.-M. Lau et al., “Calycosin orchestrates the functions of Danggui Buxue Tang, a Chinese herbal decoction composing of Astragali Radix and Angelica Sinensis Radix: an evaluation by using calycosin-knock out herbal extract,” Journal of Ethnopharmacology, vol. 168, pp. 150–157, 2015. View at: Publisher Site | Google Scholar
  6. A. G. W. Gong, K. M. Lau, M. L. Xu et al., “The estrogenic properties of Danggui Buxue Tang, a Chinese herbal decoction, are triggered predominantly by calycosin in MCF-7 cells,” Journal of Ethnopharmacology, vol. 189, pp. 81–89, 2016. View at: Publisher Site | Google Scholar
  7. W. L. Zhang, R. C.-Y. Choi, J. Y.-X. Zhan et al., “Can hedysari Radix replace astragali Radix in danggui buxue tang, a Chinese herbal decoction for woman aliment?” Phytomedicine, vol. 20, no. 12, pp. 1076–1081, 2013. View at: Publisher Site | Google Scholar
  8. W. L. Zhang, K. Y.-Z. Zheng, K. Y. Zhu et al., “Chemical and biological assessment of Angelica herbal decoction: comparison of different preparations during historical applications,” Phytomedicine, vol. 19, no. 11, pp. 1042–1048, 2012. View at: Publisher Site | Google Scholar
  9. M. R. Akanda, M. N. Uddin, I.-S. Kim, D. Ahn, H.-J. Tae, and B.-Y. Park, “The biological and pharmacological roles of polyphenol flavonoid tilianin,” European Journal of Pharmacology, vol. 842, pp. 291–297, 2019. View at: Publisher Site | Google Scholar
  10. X. Zeng, Y. Xi, and W. Jiang, “Protective roles of flavonoids and flavonoid-rich plant extracts against urolithiasis: a review,” Critical Reviews in Food Science and Nutrition, vol. 59, no. 13, pp. 2125–2135, 2019. View at: Publisher Site | Google Scholar
  11. A. G. Gong, L. M. Zhang, C. T. Lam et al., “Polysaccharide of danggui buxue tang, an ancient Chinese herbal decoction, induces expression of pro-inflammatory cytokines possibly via activation of NFκB signaling in cultured RAW 264.7 cells,” Phytotherapy Research, vol. 31, no. 2, pp. 274–283, 2017. View at: Publisher Site | Google Scholar
  12. L. Hilakivi-Clarke, C. Wang, M. Kalil, R. Riggins, and R. G. Pestell, “Nutritional modulation of the cell cycle and breast cancer,” Endocrine-Related Cancer, vol. 11, no. 4, pp. 603–622, 2004. View at: Publisher Site | Google Scholar
  13. N. Harbeck and M. Gnant, “Breast cancer,” Lancet, vol. 389, pp. 1134–1150, 2017. View at: Google Scholar
  14. J. Tian, Y. Duan, C. Bei, and J. Chen, “Calycosin induces apoptosis by upregulation of RASD1 in human breast cancer cells MCF-7,” Hormone and Metabolic Research, vol. 45, no. 08, pp. 593–598, 2013. View at: Publisher Site | Google Scholar
  15. J. Tian, Y. Wang, X. Zhang et al., “Correction to: calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 signaling,” Journal of Experimental & Clinical Cancer Research, vol. 36, no. 1, 2017. View at: Publisher Site | Google Scholar
  16. S. Li, Y. Wang, C. Feng, G. Wu, Y. Ye, and J. Tian, “Calycosin inhibits the migration and invasion of human breast cancer cells by down-regulation of Foxp3 expression,” Cellular Physiology and Biochemistry, vol. 44, no. 5, pp. 1775–1784, 2017. View at: Publisher Site | Google Scholar
  17. J. Chen, W.-B. Xiong, Y. Xiong et al., “Calycosin stimulates proliferation of estrogen receptor-positive human breast cancer cells through downregulation of Bax gene expression and upregulation of Bcl-2 gene expression at low concentrations,” Journal of Parenteral and Enteral Nutrition, vol. 35, no. 6, pp. 763–769, 2011. View at: Publisher Site | Google Scholar
  18. J. Chen, R. Hou, X. Zhang et al., “Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways,” PLoS One, vol. 9, no. 3, 2014. View at: Publisher Site | Google Scholar
  19. G. Wu, M. Niu, J. Qin, Y. Wang, and J. Tian, “Inactivation of Rab27B-dependent signaling pathway by calycosin inhibits migration and invasion of ER-negative breast cancer cells,” Gene, vol. 709, pp. 48–55, 2019. View at: Publisher Site | Google Scholar
  20. M. S. Cappell, “Pathophysiology, clinical presentation, and management of colon cancer,” Gastroenterology Clinics of North America, vol. 37, no. 1, pp. 1–24, 2008. View at: Publisher Site | Google Scholar
  21. H. J. Freeman, “Early stage colon cancer,” World Journal of Gastroenterology, vol. 19, no. 46, pp. 8468–8473, 2013. View at: Publisher Site | Google Scholar
  22. C. Huang, R. Li, W. Shi, and Z. Huang, “Discovery of the anti-tumor mechanism of calycosin against colorectal cancer by using system pharmacology approach,” Medical Science Monitor, vol. 25, pp. 5589–5593, 2019. View at: Publisher Site | Google Scholar
  23. J. Gao, Z. J. Liu, T. Chen, and D. Zhao, “Pharmaceutical properties of calycosin, the major bioactive isoflavonoid in the dry root extract of Radix astragali,” Pharmaceutical Biology, vol. 52, no. 9, pp. 1217–1222, 2014. View at: Publisher Site | Google Scholar
  24. X. J. Hu, M. Y. Xie, F. M. Kluxen, and P. Diel, “Genistein modulates the anti-tumor activity of cisplatin in MCF-7 breast and HT-29 colon cancer cells,” Archives of Toxicology, vol. 88, no. 3, pp. 625–635, 2014. View at: Publisher Site | Google Scholar
  25. X. Zhao, X. Li, Q. Ren, J. Tian, and J. Chen, “Calycosin induces apoptosis in colorectal cancer cells, through modulating the ERβ/MiR-95 and IGF-1R, PI3K/Akt signaling pathways,” Gene, vol. 591, no. 1, pp. 123–128, 2016. View at: Publisher Site | Google Scholar
  26. A. F. El-Kott, M. A. Al-Kahtani, and A. A. Shati, “Calycosin induces apoptosis in adenocarcinoma HT29 cells by inducing cytotoxic autophagy mediated by SIRT1/AMPK-induced inhibition of Akt/mTOR,” Clinical and Experimental Pharmacology and Physiology, vol. 46, no. 10, pp. 944–954, 2019. View at: Publisher Site | Google Scholar
  27. Q. Wang, W. Lu, T. Yin et al., “Correction to: calycosin suppresses TGF-β-induced epithelial-to-mesenchymal transition and migration by upregulating BATF2 to target PAI-1 via the Wnt and PI3K/Akt signaling pathways in colorectal cancer cells,” Journal of Experimental & Clinical Cancer Research, vol. 38, no. 1, 2019. View at: Publisher Site | Google Scholar
  28. J. Chen, X. Zhao, X. Li et al., “Calycosin induces apoptosis by the regulation of ERβ/miR-17 signaling pathway in human colorectal cancer cells,” Food Funct, vol. 6, no. 7, pp. 3091–3097, 2015. View at: Publisher Site | Google Scholar
  29. M. F. Wedekind, L. M. Wagner, and T. P. Cripe, “Immunotherapy for osteosarcoma: where do we go from here?” Pediatr Blood Cancer, vol. 65, no. 9, 2018. View at: Publisher Site | Google Scholar
  30. S. Miwa, T. Shirai, N. Yamamoto et al., “Current and emerging targets in immunotherapy for osteosarcoma,” Journal of Oncology, vol. 2019, Article ID 7035045, 8 pages, 2019. View at: Publisher Site | Google Scholar
  31. R. Qiu, X. Li, K. Qin et al., “Antimetastatic effects of calycosin on osteosarcoma and the underlying mechanism,” Biofactors, vol. 45, no. 6, pp. 975–982, 2019. View at: Publisher Site | Google Scholar
  32. Y. Wang, Q. Ren, X. Zhang, H. Lu, and J. Chen, “Neuroprotective mechanisms of calycosin against focal cerebral ischemia and reperfusion injury in rats,” Cellular Physiology and Biochemistry, vol. 45, no. 2, pp. 537–546, 2018. View at: Publisher Site | Google Scholar
  33. W. Tian, Z. W. Wang, B. M. Yuan et al., “Calycosin induces apoptosis in osteosarcoma cell line via ERβ-mediated PI3K/Akt signaling pathways,” Molecular Medicine Reports, vol. 21, no. 6, pp. 2349–2356, 2020. View at: Publisher Site | Google Scholar
  34. J. S. Lou, L. Yan, C. W. Bi et al., “Yu Ping Feng San reverses cisplatin-induced multi-drug resistance in lung cancer cells via regulating drug transporters and p62/TRAF6 signalling,” Scientific Report, vol. 6, 2016. View at: Publisher Site | Google Scholar
  35. G. Gong, H. Wang, X. Kong et al., “Flavonoids are identified from the extract of Scutellariae Radix to suppress inflammatory-induced angiogenic responses in cultured RAW 264.7 macrophages,” Scientific Report, vol. 8, 2018. View at: Publisher Site | Google Scholar
  36. J. Zhai, L. Tao, S. Zhang et al., “Calycosin ameliorates doxorubicin‐induced cardiotoxicity by suppressing oxidative stress and inflammation via the sirtuin 1-NOD‐like receptor protein 3 pathway,” Phytotherapy Research, vol. 34, no. 3, pp. 649–659, 2020. View at: Publisher Site | Google Scholar
  37. C.-Y. Chen, Y.-G. Zu, Y.-J. Fu et al., “Preparation and antioxidant activity of Radix Astragali residues extracts rich in calycosin and formononetin,” Biochemical Engineering Journal, vol. 56, no. 1-2, pp. 84–93, 2011. View at: Publisher Site | Google Scholar
  38. B. Liu, J. Zhang, W. Liu et al., “Calycosin inhibits oxidative stress-induced cardiomyocyte apoptosis via activating estrogen receptor-α/β,” Bioorganic & Medicinal Chemistry Letters, vol. 26, no. 1, pp. 181–185, 2016. View at: Publisher Site | Google Scholar
  39. X. Wang and L. Zhao, “Calycosin ameliorates diabetes-induced cognitive impairments in rats by reducing oxidative stress via the PI3K/Akt/GSK-3β signaling pathway,” Biochemical and Biophysical Research Communications, vol. 473, no. 2, pp. 428–434, 2016. View at: Publisher Site | Google Scholar
  40. N. M. Elsherbiny, E. Said, H. Atef et al., “Renoprotective effect of calycosin in high fat diet-fed/STZ injected rats: effect on IL-33/ST2 signaling, oxidative stress and fibrosis suppression,” Chemico-Biological Interactions, vol. 315, 2020. View at: Publisher Site | Google Scholar
  41. R. Ma, F. Yuan, S. Wang, Y. Liu, T. Fan, and F. Wang, “Calycosin alleviates cerulein-induced acute pancreatitis by inhibiting the inflammatory response and oxidative stress via the p38 MAPK and NF-κB signal pathways in mice,” Biomedicine & Pharmacotherapy, vol. 105, pp. 599–605, 2018. View at: Publisher Site | Google Scholar
  42. C. Chen, J. Cui, X. Ji, and L. Yao, “Neuroprotective functions of calycosin against intracerebral hemorrhage-induced oxidative stress and neuroinflammation,” Future Medicinal Chemistry, vol. 12, no. 7, pp. 583–592, 2020. View at: Publisher Site | Google Scholar
  43. L. Lu, X. Zhao, J. Zhang, M. Li, Y. Qi, and L. Zhou, “Calycosin promotes lifespan in Caenorhabditis elegans through insulin signaling pathway via daf-16, age-1 and daf-2,” Journal of Bioscience and Bioengineering, vol. 124, no. 1, pp. 1–7, 2017. View at: Publisher Site | Google Scholar
  44. L. Dong, L. Yin, R. Chen et al., “Anti-inflammatory effect of calycosin glycoside on lipopolysaccharide-induced inflammatory responses in RAW 264.7 cells,” Gene, vol. 675, pp. 94–101, 2018. View at: Publisher Site | Google Scholar
  45. R. L. Hoo, J. Y. Wong, C. Qiao et al., “The effective fraction isolated from Radix Astragali alleviates glucose intolerance, insulin resistance and hypertriglyceridemia in db/db diabetic mice through its anti-inflammatory activity,” Nutrition & Metabolism (London), vol. 7, 2010. View at: Publisher Site | Google Scholar
  46. J. L. Figarola, N. Shanmugam, R. Natarajan, and S. Rahbar, “Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes,” Diabetes, vol. 56, no. 3, pp. 647–655, 2007. View at: Publisher Site | Google Scholar
  47. J. W. Kim, Y. C. Jin, Y. M. Kim et al., “Daidzein administration in vivo reduces myocardial injury in a rat ischemia/reperfusion model by inhibiting NF-kappaB activation,” Life Sci, vol. 84, no. 7, pp. 227–234, 2009. View at: Publisher Site | Google Scholar
  48. C. C. Cheng, Y. H. Chen, W. L. Chang et al., “Phytoestrogen bavachin mediates anti-inflammation targeting Ikappa B kinase-IkappaB alpha-NF-kappaB signaling pathway in chondrocytes in vitro,” European Journal of Pharmacology, vol. 636, pp. 181–188, 2010. View at: Publisher Site | Google Scholar
  49. Y. Xu, J. Xiong, Y. Zhao et al., “Calycosin rebalances advanced glycation end products-induced glucose uptake dysfunction of hepatocyte in vitro,” The American Journal of Chinese Medicine, vol. 43, no. 06, pp. 1191–1210, 2015. View at: Publisher Site | Google Scholar
  50. Y.-Y. Zhang, R.-Z. Tan, X.-Q. Zhang, Y. Yu, and C. Yu, “Calycosin ameliorates diabetes-induced renal inflammation via the NF-κB pathway in vitro and in vivo,” Medical Science Monitor, vol. 25, pp. 1671–1678, 2019. View at: Publisher Site | Google Scholar
  51. N. Li, Y. Tu, Y. Shen, Y. Qin, C. Lei, and X. Liu, “Calycosin attenuates osteoporosis and regulates the expression of OPG/RANKL in ovariectomized rats via MAPK signaling,” Die Pharmazie, vol. 71, no. 10, pp. 607–612, 2016. View at: Publisher Site | Google Scholar
  52. A. G. Gong, R. Duan, H. Y. Wang et al., “Calycosin orchestrates osteogenesis of Danggui Buxue Tang in cultured osteoblasts: evaluating the mechanism of action by omics and chemical knock-out methodologies,” Frontiers in Pharmacology, vol. 9, 2018. View at: Publisher Site | Google Scholar
  53. X. Kong, F. Wang, Y. Niu, X. Wu, and Y. Pan, “A comparative study on the effect of promoting the osteogenic function of osteoblasts using isoflavones from Radix Astragalus,” Phytotherapy Research, vol. 32, no. 1, pp. 115–124, 2018. View at: Publisher Site | Google Scholar
  54. Y. Fang, Z. Xue, L. Zhao et al., “Calycosin stimulates the osteogenic differentiation of rat calvarial osteoblasts by activating the IGF1R/PI3K/Akt signaling pathway,” Cell Biology International, vol. 43, no. 3, pp. 323–332, 2019. View at: Publisher Site | Google Scholar
  55. G.-H. Quan, H. Wang, J. Cao et al., “Calycosin suppresses RANKL-mediated osteoclastogenesis through inhibition of MAPKs and NF-κB,” International Journal of Molecular Sciences, vol. 16, no. 12, pp. 29496–29507, 2015. View at: Publisher Site | Google Scholar
  56. K. Y. Z. Zheng, R. C. Y. Choi, A. W. H. Cheung et al., “Flavonoids from Radix astragali induce the expression of erythropoietin in cultured cells: a signaling mediated via the accumulation of hypoxia-inducible factor-1α,” Journal of Agricultural and Food Chemistry, vol. 59, no. 5, pp. 1697–1704, 2011. View at: Publisher Site | Google Scholar
  57. W. Zhang, J. H. Zhu, H. Xu et al., “Five active components compatibility of Astragali Radix and Angelicae Sinensis Radix protect hematopoietic function against cyclophosphamide-induced injury in mice and t-BHP-induced injury in HSCs,” Frontiers in Pharmacology, vol. 10, 2019. View at: Publisher Site | Google Scholar
  58. C. Guo, L. Tong, M. Xi, H. Yang, H. Dong, and A. Wen, “Neuroprotective effect of calycosin on cerebral ischemia and reperfusion injury in rats,” Journal of Ethnopharmacology, vol. 144, no. 3, pp. 768–774, 2012. View at: Publisher Site | Google Scholar
  59. Y. Wang, X. Dong, Z. Li et al., “Downregulated RASD1 and upregulated miR-375 are involved in protective effects of calycosin on cerebral ischemia/reperfusion rats,” Journal of the Neurological Sciences, vol. 339, pp. 144–148, 2014. View at: Publisher Site | Google Scholar
  60. C.-C. Hsu, T.-W. Kuo, W.-P. Liu, C.-P. Chang, and H.-J. Lin, “Calycosin preserves BDNF/TrkB signaling and reduces post-stroke neurological injury after cerebral ischemia by reducing accumulation of hypertrophic and TNF-α-containing microglia in rats,” Journal of Neuroimmune Pharmacology, vol. 15, no. 2, pp. 326–339, 2020. View at: Publisher Site | Google Scholar
  61. D.-H. Yu, Y.-M. Bao, L.-J. An, and M. Yang, “Protection of PC12 cells against superoxide-induced damage by isoflavonoids from Astragalus mongholicus,” Biomedical and Environmental Sciences, vol. 22, no. 1, pp. 50–54, 2009. View at: Publisher Site | Google Scholar
  62. D. H. Yu, Y. L. Duan, Y. M. Bao et al., “Isoflavonoids from Astragalus mongholicus protect PC12 cells from toxicity induced by L-glutamate,” Journal of Ethnopharmacology, vol. 98, no. 1-2, pp. 89–94, 2005. View at: Publisher Site | Google Scholar
  63. L. Song, X. Li, X. X. Bai, J. Gao, and C. Y. Wang, “Calycosin Improves cognitive function in a transgenic mouse model of Alzheimer’s disease by activating the protein kinase C pathway,” Neural Regeneration Research, vol. 12, no. 11, pp. 1870–1876, 2017. View at: Publisher Site | Google Scholar
  64. J. Yang, M. Jia, X. Zhang, and P. Wang, “Calycosin attenuates MPTP-induced Parkinson’s disease by suppressing the activation of TLR/NF-κB and MAPK pathways,” Phytotherapy Research, vol. 33, no. 2, pp. 309–318, 2019. View at: Publisher Site | Google Scholar
  65. Y. Wang, P. Wang, J. Xie et al., “Pharmacokinetic comparisons of different combinations of Yigan Jiangzhi formula in rats: simultaneous determination of fourteen components by UPLC-MS/MS,” Journal of Analytical Methods in Chemistry, vol. 2020, Article ID 9353975, 16 pages, 2020. View at: Publisher Site | Google Scholar
  66. R. Liu, R. Ma, C. Yu et al., “Quantitation of eleven active compounds of Aidi injection in rat plasma and its application to comparative pharmacokinetic study,” Journal of Chromatography B, vol. 1026, pp. 105–113, 2016. View at: Publisher Site | Google Scholar
  67. M. Liu, P. Li, X. Zeng et al., “Identification and pharmacokinetics of multiple potential bioactive constituents after oral administration of Radix Astragali on cyclophosphamide-induced immunosuppression in Balb/c mice,” International Journal of Molecular Sciences, vol. 16, no. 3, pp. 5047–5071, 2015. View at: Publisher Site | Google Scholar
  68. H. Zhao, Y. Zhang, Y. Guo, and S. Shi, “Identification of major α-glucosidase inhibitors in Radix Astragali and its human microsomal metabolites using ultrafiltration HPLC-DAD-MS(n),” Journal of Pharmaceutical and Biomedical Analysis, vol. 104, pp. 31–37, 2015. View at: Publisher Site | Google Scholar
  69. X.-D. Wen, L.-W. Qi, B. Li et al., “Microsomal metabolism of calycosin, formononetin and drug-drug interactions by dynamic microdialysis sampling and HPLC-DAD-MS analysis,” Journal of Pharmaceutical and Biomedical Analysis, vol. 50, no. 1, pp. 100–105, 2009. View at: Publisher Site | Google Scholar
  70. X. Tian, S. Chen, Y. Zhang et al., “Absorption, liver first-pass effect, pharmacokinetics and tissue distribution of calycosin-7-O-ß-d-glucopyranoside (C7G) and its major active metabolite, calycosin, following oral administration of C7G in rats by LC-MS/MS,” Journal of Pharmaceutical and Biomedical Analysis, vol. 148, pp. 350–354, 2018. View at: Publisher Site | Google Scholar
  71. J. Guan, L. Wang, J. Jin et al., “Simultaneous determination of calycosin-7-O-β-D-glucoside, cinnamic acid, paeoniflorin and albiflorin in rat plasma by UHPLC-MS/MS and its application to a pharmacokinetic study of Huangqi Guizhi Wuwu decoction,” Journal of Pharmaceutical and Biomedical Analysis, vol. 170, pp. 1–7, 2019. View at: Publisher Site | Google Scholar
  72. Y.-Z. Zhang, F. Xu, J. Dong et al., “Profiling and identification of the metabolites of calycosin in rat hepatic 9000 × g supernatant incubation system and the metabolites of calycosin-7-O-β-D-glucoside in rat urine by HPLC-DAD-ESI-IT-TOF-MS(n) technique,” Journal of Pharmaceutical and Biomedical Analysis, vol. 70, pp. 425–439, 2012. View at: Publisher Site | Google Scholar
  73. F. Zhang, Y. Zhang, X. Li et al., “Research on Q-markers of Qiliqiangxin capsule for chronic heart failure treatment based on pharmacokinetics and pharmacodynamics association,” Phytomedicine, vol. 44, pp. 220–230, 2018. View at: Publisher Site | Google Scholar
  74. Q. Lin, Y. Li, X. M. Tan et al., “Simultaneous determination of formononetin, calycosin and isorhamnetin from Astragalus mongholicus in rat plasma by LC-MS/MS and application to pharmacokinetic study,” Zhong Yao Cai, vol. 36, no. 4, pp. 589–593, 2013. View at: Google Scholar
  75. L. Chen, Z. Li, Y. Tang et al., “Isolation, identification and antiviral activities of metabolites of calycosin-7-O-β-d-glucopyranoside,” Journal of Pharmaceutical and Biomedical Analysis, vol. 56, no. 2, pp. 382–389, 2011. View at: Publisher Site | Google Scholar
  76. G. Zhang, R. Ou, F. Li et al., “Regulation of drug-metabolizing enzymes and efflux transporters by Astragali radix decoction and its main bioactive compounds: implication for clinical drug-drug interactions,” Journal of Ethnopharmacology, vol. 180, pp. 104–113, 2016. View at: Publisher Site | Google Scholar
  77. K. Y. Z. Zheng, R. C. Y. Choi, H. Q. H. Xie et al., “The expression of erythropoietin triggered by Danggui Buxue Tang, a Chinese herbal decoction prepared from Radix Astragali and Radix Angelicae Sinensis, is mediated by the hypoxia-inducible factor in cultured HEK293T,” Journal of Ethnopharmacology, vol. 132, no. 1, pp. 259–267, 2010. View at: Publisher Site | Google Scholar
  78. K. Y.-Z. Zheng, R. C.-Y. Choi, A. J.-Y. Guo et al., “The membrane permeability of Astragali Radix-derived formononetin and calycosin is increased by Angelicae Sinensis Radix in Caco-2 cells: a synergistic action of an ancient herbal decoction Danggui Buxue Tang,” Journal of Pharmaceutical and Biomedical Analysis, vol. 70, pp. 671–679, 2012. View at: Publisher Site | Google Scholar
  79. L. Zhang, A. G. W. Gong, K. Riaz et al., “A novel combination of four flavonoids derived from Astragali Radix relieves the symptoms of cyclophosphamide-induced anemic rats,” FEBS Open Bio, vol. 7, no. 3, pp. 318–323, 2017. View at: Publisher Site | Google Scholar
  80. P. Zhao, W. C. Zhou, D. L. Li et al., “Total glucosides of Danggui Buxue Tang attenuate BLM-induced pulmonary fibrosis via regulating oxidative stress by inhibiting NOX4,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 645814, 10 pages, 2015. View at: Publisher Site | Google Scholar
  81. B. Wu, X. F. Sun, and G. Y. Yang, “Studies on different combination of the dang gui buxue decoction,” Chinese Medicine Material, vol. 4, pp. 41–45, 1989. View at: Google Scholar
  82. Y. Lei and K. J. Chen, “Study on angiogenesis effect of Radix astragali, Radix Angelicae sinensis & their combination,” Chinese Medical Sciences, vol. 4, pp. 110–117, 2003. View at: Google Scholar
  83. X. Yang, C.-G. Huang, S.-Y. Du et al., “Effect of Danggui Buxue Tang on immune-mediated aplastic anemia bone marrow proliferation mice,” Phytomedicine, vol. 21, no. 5, pp. 640–646, 2014. View at: Publisher Site | Google Scholar
  84. J.-H. Xie, Z.-W. Chen, Y.-W. Pan et al., “Evaluation of safety of modified-Danggui Buxue Tang in rodents:immunological, toxicity and hormonal aspects,” Journal of Ethnopharmacology, vol. 183, pp. 59–70, 2016. View at: Publisher Site | Google Scholar
  85. Y. Y. Choi, M. H. Kim, J. Hong et al., “Effect of Dangguibohyul-Tang, a mixed extract of Astragalus membranaceus and Angelica sinensis, on allergic and inflammatory skin reaction compared with single extracts of Astragalus membranaceus or Angelica sinensis,” Evid Based Complement Altern Med, vol. 2016, Article ID 5936354, 9 pages, 2016. View at: Publisher Site | Google Scholar

Copyright © 2021 Guowei Gong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views495
Downloads528
Citations

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.